#dc-system-status for updates. The development team can be contacted at datacentre@scilifelab.se if you have any question.Antibody Response Before and After the Booster Dose of Inactivated Corona Vaccine in Antibody Deficient Patients.
JSON
Movahedi M, Movahedi M, Parvaneh N, Abolhassani H, Mahdavi M, Mosavikhorshidi MS, Alizadeh F, Shokri M, Kalantari A
Iran J Allergy Asthma Immunol 23 (2) 158-167 [2024-04-07; online 2024-04-07]
Patients with inborn errors of immunity (IEI) are among the high-risk groups regarding COVID-19. Receiving booster doses (third and fourth) in addition to the standard doses is recommended in these patients. This study investigated the antibody response before and after a booster dose of Sinopharm vaccine in IEI patients. Thirty patients (>12 years) with antibody deficiencies, referred to Imam Khomeini Hospital and Children's Medical Center in Tehran, were enrolled in this prospective cross-sectional study. All patients were fully vaccinated with the BBIBP-CorV vaccine (2 doses of Sinopharm). Initial measurements of anti-receptor-binding domain (anti-RBD) and anti-nucleocapsid (anti-N) IgG antibody responses were conducted by enzyme-linked immunosorbent assay (ELISA). Subsequently, all patients received a booster dose of the vaccine. Four to six weeks after booster injection, the levels of antibodies were re-evaluated. Twenty patients with common variable immunodeficiency (CVID), 7 cases with agammaglobulinemia and 3 patients with hyper IgM syndrome were studied. Anti-RBD IgG and anti-N IgG antibodies increased in all patients after the booster. Our results indicated the need of receiving booster doses of the COVID-19 vaccine in patients with antibody deficiencies, even for enhancing humoral immune response specially in patients with CVID.
PubMed 38822511
DOI 10.18502/ijaai.v23i2.15322
Crossref 10.18502/ijaai.v23i2.15322